Giovanni A Fava

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3204782/publications.pdf

Version: 2024-02-01

144 papers 9,742 citations

28274 55 h-index 94 g-index

144 all docs

144 docs citations

times ranked

144

6788 citing authors

#	Article	IF	CITATIONS
1	An innovative approach to the assessment of mood disturbances in patients with acute coronary syndrome. CNS Spectrums, 2023, 28, 78-89.	1.2	9
2	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. International Journal of Clinical and Health Psychology, 2022, 22, 100279.	5.1	5
3	Forty Years of Clinimetrics. Psychotherapy and Psychosomatics, 2022, 91, 1-7.	8.8	20
4	The Clinical Science of Euthymia: A Conceptual Map. Psychotherapy and Psychosomatics, 2022, 91, 156-167.	8.8	25
5	The Age of Transition. Psychotherapy and Psychosomatics, 2021, 90, 1-4.	8.8	6
6	Benzodiazepines: it's time to return to the evidence. British Journal of Psychiatry, 2021, 218, 125-127.	2.8	26
7	Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder. JAMA Psychiatry, 2021, 78, 261.	11.0	77
8	Allostatic Load and Its Impact on Health: A Systematic Review. Psychotherapy and Psychosomatics, 2021, 90, 11-27.	8.8	441
9	When the Label Does Not Match the Content of a Trial: "Wellâ€Being Therapy―in Posttraumatic Stress Disorder: Commentary on Radstaak etÂal. (2020). Journal of Traumatic Stress, 2021, 34, 467-469.	1.8	3
10	When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria. Psychotherapy and Psychosomatics, 2021, 90, 308-317.	8.8	27
11	Clinimetric Criteria for Patient-Reported Outcome Measures. Psychotherapy and Psychosomatics, 2021, 90, 222-232.	8.8	84
12	Conceptual and Clinical Innovations of Well-being Therapy. International Journal of Cognitive Therapy, 2021, 14, 196-208.	2.2	10
13	Prodromal Symptoms in Depression: A Systematic Review. Psychotherapy and Psychosomatics, 2021, 90, 365-372.	8.8	24
14	Are the Same Medications that Are Used in the Acute Treatment of Depression the Most Suitable for Preventing Relapse?. Journal of Clinical Psychopharmacology, 2021, 41, 617-619.	1.4	2
15	Prescribing Pharmacotherapy for Major Depressive Disorder: How Does a Clinician Decide?. Biomedicine Hub, 2021, 6, 118-121.	1.2	2
16	An innovative approach for the assessment of mood disturbances in patients with eating disorders. CNS Spectrums, 2020, 25, 71-78.	1.2	8
17	The pursuit of euthymia. World Psychiatry, 2020, 19, 40-50.	10.4	104
18	The Decline of Pluralism in Medicine: Dissent Is Welcome. Psychotherapy and Psychosomatics, 2020, 89, 1-5.	8.8	29

#	Article	IF	CITATIONS
19	May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532097032.	2.7	36
20	Relapse prevention in recurrent major depressive disorder. A comparison of different treatment options based on clinical experience and a critical review of the literature. International Journal of Psychiatry in Clinical Practice, 2020, 24, 341-348.	2.4	12
21	Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations. Expert Review of Neurotherapeutics, 2020, 20, 1169-1175.	2.8	16
22	The emerging role of euthymia in psychotherapy research and practice. Clinical Psychology Review, 2020, 82, 101941.	11.4	26
23	The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry, 2020, 19, 269-293.	10.4	174
24	Sequential Combination of Cognitive-Behavioral Treatment and Well-Being Therapy in Depressed Patients with Acute Coronary Syndromes: A Randomized Controlled Trial (TREATED-ACS Study). Psychotherapy and Psychosomatics, 2020, 89, 345-356.	8.8	31
25	Kellner's Symptom Questionnaire, a Highly Sensitive Patient-Reported Outcome Measure: Systematic Review of Clinimetric Properties. Psychotherapy and Psychosomatics, 2020, 89, 74-89.	8.8	29
26	The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem. Psychotherapy and Psychosomatics, 2020, 89, 265-273.	8.8	27
27	The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions. Psychotherapy and Psychosomatics, 2020, 89, 133-150.	8.8	133
28	Reply to Alacreu-Crespo et al Psychotherapy and Psychosomatics, 2020, 89, 324-325.	8.8	0
29	The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed. Revista Brasileira De Psiquiatria, 2020, 42, 243-244.	1.7	13
30	Mental Pain as a Transdiagnostic Patient-Reported Outcome Measure. Psychotherapy and Psychosomatics, 2019, 88, 341-349.	8.8	44
31	The Journal's Mission. Psychotherapy and Psychosomatics, 2019, 88, 1-4.	8.8	8
32	latrogenic Factors in Psychopathology. Psychotherapy and Psychosomatics, 2019, 88, 129-140.	8.8	64
33	Clinical characterization of allostatic overload. Psychoneuroendocrinology, 2019, 108, 94-101.	2.7	172
34	Addressing Clinical Challenges of Antidepressant Discontinuation. American Journal of Psychiatry, 2019, 176, 487-488.	7.2	5
35	Reply to the Letter to the Editor: "ls A Single-Item Measure of Self-Rated Mental Health Useful from a Clinimetric Perspective?― Psychotherapy and Psychosomatics, 2019, 88, 179-179.	8.8	4
36	Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. Journal of Clinical Psychiatry, 2019, 80, .	2.2	32

3

#	Article	lF	Citations
37	The Emerging Role of Clinical Pharmacopsychology. Clinical Psychology in Europe, 2019, 1, .	1.1	5
38	Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychotherapy and Psychosomatics, 2018, 87, 65-74.	8.8	56
39	Time to rethink the approach to recurrent depression. Lancet Psychiatry, the, 2018, 5, 380-381.	7.4	3
40	Overcoming the Crisis of Clinical Research. Psychotherapy and Psychosomatics, 2018, 87, 1-4.	8.8	10
41	What psychologists need to know about psychotropic medications. Clinical Psychology and Psychotherapy, 2018, 25, 181-187.	2.7	6
42	The clinical role of well-being therapy. Nordic Journal of Psychiatry, 2018, 72, 447-453.	1.3	79
43	The Clinimetric Approach to Psychological Assessment: A Tribute to Per Bech, MD (1942–2018). Psychotherapy and Psychosomatics, 2018, 87, 321-326.	8.8	112
44	Methodological Recommendations for Trials of Psychological Interventions. Psychotherapy and Psychosomatics, 2018, 87, 276-284.	8.8	146
45	Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychotherapy and Psychosomatics, 2018, 87, 195-203.	8.8	133
46	The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Medicine, 2018, 16, 112.	5.5	143
47	Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience. Psychotherapy and Psychosomatics, 2018, 87, 257-267.	8.8	56
48	The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability. Rivista Di Psichiatria, 2018, 53, 95-99.	0.6	13
49	Current Psychosomatic Practice. Psychotherapy and Psychosomatics, 2017, 86, 13-30.	8.8	205
50	Well-being therapy in depression: New insights into the role of psychological well-being in the clinical process. Depression and Anxiety, 2017, 34, 801-808.	4.1	61
51	Clinical Pharmacopsychology: Conceptual Foundations and Emerging Tasks. Psychotherapy and Psychosomatics, 2017, 86, 134-140.	8.8	42
52	Evidence-based medicine was bound to fail: a report to Alvan Feinstein. Journal of Clinical Epidemiology, 2017, 84, 3-7.	5.0	56
53	From the Lesson of George Engel to Current Knowledge: The Biopsychosocial Model 40 Years Later. Psychotherapy and Psychosomatics, 2017, 86, 257-259.	8.8	32
54	The Clinical Inadequacy of the Placebo Model and the Development of an Alternative Conceptual Framework. Psychotherapy and Psychosomatics, 2017, 86, 332-340.	8.8	75

#	Article	IF	CITATIONS
55	The Role of Staging in Planning Psychotherapeutic Interventions in Depression. Journal of Clinical Psychiatry, 2017, 78, 456-463.	2.2	32
56	The Hidden Costs of Financial Conflicts of Interest in Medicine. Psychotherapy and Psychosomatics, 2016, 85, 65-70.	8.8	20
57	The clinical inadequacy of the DSM-5 classification of somatic symptom and related disorders: an alternative trans-diagnostic model. CNS Spectrums, 2016, 21, 310-317.	1.2	45
58	Well-Being Therapy: Current Indications and Emerging Perspectives. Psychotherapy and Psychosomatics, 2016, 85, 136-145.	8.8	63
59	The Concept of Euthymia. Psychotherapy and Psychosomatics, 2016, 85, 1-5.	8.8	158
60	The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and Psychosomatics, 2016, 85, 270-288.	8.8	428
61	Behavioral Toxicity Revisited. Journal of Clinical Psychopharmacology, 2016, 36, 550-553.	1.4	47
62	The Assessment of Allostatic Overload in Patients with Congestive Heart Failure by Clinimetric Criteria. Stress and Health, 2016, 32, 63-69.	2.6	20
63	The Sequential Integration of Pharmacotherapy and Psychotherapy in the Treatment of Major Depressive Disorder: A Meta-Analysis of the Sequential Model and a Critical Review of the Literature. American Journal of Psychiatry, 2016, 173, 128-137.	7.2	117
64	Psychological aspects of hyperandrogenic states in late adolescent and young women. Clinical Endocrinology, 2015, 83, 872-878.	2.4	30
65	The Clinical Inadequacy of Evidence-Based Medicine and the Need for a Conceptual Framework Based on Clinical Judgment. Psychotherapy and Psychosomatics, 2015, 84, 1-3.	8.8	53
66	Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and Psychosomatics, 2015, 84, 72-81.	8.8	319
67	Need for a realistic appraisal of benzodiazepines. World Psychiatry, 2015, 14, 243-244.	10.4	17
68	Clinical Methodology Matters in Epidemiology: Not All Benzodiazepines Are the Same. Psychotherapy and Psychosomatics, 2015, 84, 262-264.	8.8	24
69	Benzodiazepines in Anxiety Disorders. JAMA Psychiatry, 2015, 72, 733.	11.0	9
70	The Psychosomatic Practice. Acta Dermato-Venereologica, 2014, 96, 9-13.	1.3	5
71	Road to nowhere. World Psychiatry, 2014, 13, 49-50.	10.4	18
72	Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research. International Journal of Methods in Psychiatric Research, 2014, 23, 92-101.	2.1	25

#	Article	IF	CITATIONS
73	The Independence of Medical Journals and the Deceptive Effects of Open Access. Psychotherapy and Psychosomatics, 2014, 83, 1-5.	8.8	8
74	The Missing Link between Clinical States and Biomarkers in Mental Disorders. Psychotherapy and Psychosomatics, 2014, 83, 136-141.	8.8	32
75	Rational Use of Antidepressant Drugs. Psychotherapy and Psychosomatics, 2014, 83, 197-204.	8.8	80
76	Efficacy and Tolerability of Benzodiazepines versus Antidepressants in Anxiety Disorders: A Systematic Review and Meta-Analysis. Psychotherapy and Psychosomatics, 2013, 82, 355-362.	8.8	138
77	Clinical judgment in psychiatry. Requiem or reveille?. Nordic Journal of Psychiatry, 2013, 67, 1-10.	1.3	27
78	Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 306-311.	4.8	40
79	Staging of Mental Disorders: Systematic Review. Psychotherapy and Psychosomatics, 2013, 82, 20-34.	8.8	185
80	Excessive Mood Elevation and Behavioral Activation with Antidepressant Treatment of Juvenile Depressive and Anxiety Disorders: A Systematic Review. Psychotherapy and Psychosomatics, 2013, 82, 132-141.	8.8	86
81	The clinical role of psychological wellâ€being. World Psychiatry, 2012, 11, 102-103.	10.4	20
82	Treatment Selection in Depression: The Role of Clinical Judgment. Psychiatric Clinics of North America, 2012, 35, 87-98.	1.3	31
83	Clinical configuration of cyclothymic disturbances. Journal of Affective Disorders, 2012, 139, 244-249.	4.1	20
84	The Clinical Process in Psychiatry. Journal of Clinical Psychiatry, 2012, 73, 177-184.	2.2	118
85	The Sequential Combination of Cognitive Behavioral Treatment and Well-Being Therapy in Cyclothymic Disorder. Psychotherapy and Psychosomatics, 2011, 80, 136-143.	8.8	136
86	The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1593-1602.	4.8	123
87	The Clinical Interview for Depression: A Comprehensive Review of Studies and Clinimetric Properties. Psychotherapy and Psychosomatics, 2011, 80, 10-27.	8.8	75
88	Psychological Characterization of Demoralization in the Setting of Heart Transplantation. Journal of Clinical Psychiatry, 2011, 72, 648-654.	2.2	39
89			
69	Psychosomatic Medicine is a Comprehensive Field, Not a Synonym for Consultation Liaison Psychiatry. Current Psychiatry Reports, 2010, 12, 215-221.	4. 5	32

#	Article	IF	Citations
91	New Modalities of Assessment and Treatment Planning in Depression. CNS Drugs, 2010, 24, 453-465.	5.9	64
92	The Spectrum of Anxiety Disorders in the Medically Ill. Journal of Clinical Psychiatry, 2010, 71, 910-914.	2.2	57
93	The Decline of Pharmaceutical Psychiatry and the Increasing Role of Psychological Medicine. Psychotherapy and Psychosomatics, 2009, 78, 220-227.	8.8	31
94	<i>Psychotherapy and Psychosomatics: </i> A Tribute to Peter E. Sifneos, MD (1920–2008). Psychotherapy and Psychosomatics, 2009, 78, 328-329.	8.8	2
95	Psychosomatic Assessment. Psychotherapy and Psychosomatics, 2009, 78, 333-341.	8.8	73
96	The Sequential Combination of Pharmacotherapy and Psychotherapy in Mood Disorders. Journal of Contemporary Psychotherapy, 2009, 39, 101-109.	1.2	11
97	Increasing Psychological Wellâ€Being and Resilience by Psychotherapeutic Methods. Journal of Personality, 2009, 77, 1903-1934.	3.2	293
98	Agoraphobia Is a Disease: A Tribute to Sir Martin Roth. Psychotherapy and Psychosomatics, 2008, 77, 133-138.	8.8	41
99	The mental health clinic: a new model. World Psychiatry, 2008, 7, 177-181.	10.4	16
100	Psychosocial determinants of recovery in depression. Dialogues in Clinical Neuroscience, 2008, 10, 461-472.	3.7	11
101	Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. International Journal of Neuropsychopharmacology, 2007, 10, 835-8.	2.1	67
102	Psychological Factors Affecting Medical Condition: A New Proposal for DSM-V. Psychosomatics, 2007, 48, 103-111.	2.5	81
103	The Road to Recovery from Depression – Don't Drive Today with Yesterday's Map. Psychotherapy and Psychosomatics, 2007, 76, 260-265.	8.8	103
104	Prodromal stage of major depression. Microbial Biotechnology, 2007, 1, 9-18.	1.7	66
105	Family Intervention Approach to Loss of Clinical Effect During Long-Term Antidepressant Treatment. Journal of Clinical Psychiatry, 2007, 68, 1348-1351.	2.2	17
106	Financial conflicts of interest in psychiatry. World Psychiatry, 2007, 6, 19-24.	10.4	31
107	The Intellectual Crisis of Psychiatric Research. Psychotherapy and Psychosomatics, 2006, 75, 202-208.	8.8	72
108	Treatment of recurrent depression. Expert Review of Neurotherapeutics, 2006, 6, 1735-1740.	2.8	20

#	Article	IF	Citations
109	Well-Being Therapy of Generalized Anxiety Disorder. Psychotherapy and Psychosomatics, 2005, 74, 26-30.	8.8	292
110	A discussion on the role of clinimetrics and the misleading effects of psychometric theory. Journal of Clinical Epidemiology, 2005, 58, 753-756.	5.0	40
111	The Clinical Domains of Psychosomatic Medicine. Journal of Clinical Psychiatry, 2005, 66, 849-858.	2.2	74
112	Sequential Treatment of Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2005, 66, 1392-1400.	2.2	74
113	Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression. American Journal of Psychiatry, 2004, 161, 1872-1876.	7.2	299
114	Psychometric Theory Is an Obstacle to the Progress of Clinical Research. Psychotherapy and Psychosomatics, 2004, 73, 145-148.	8.8	127
115	Development and characteristics of a well-being enhancing psychotherapeutic strategy: well-being therapy. Journal of Behavior Therapy and Experimental Psychiatry, 2003, 34, 45-63.	1.2	293
116	Treatment of Recurrent Depression. CNS Drugs, 2003, 17, 1109-1117.	5.9	46
117	Management of Recurrent Depression in Primary Care. Psychotherapy and Psychosomatics, 2003, 72, 3-9.	8.8	32
118	Can Long-Term Treatment With Antidepressant Drugs Worsen the Course of Depression?. Journal of Clinical Psychiatry, 2003, 64, 123-133.	2.2	185
119	Cognitive Behavior Approach to Loss of Clinical Effect During Long-Term Antidepressant Treatment: A Pilot Study. American Journal of Psychiatry, 2002, 159, 2094-2095.	7.2	84
120	Psychiatric Disorders Associated with Cushing??s Syndrome. CNS Drugs, 2001, 15, 361-373.	5.9	219
121	Assessment of subclinical symptoms and psychological well-being in depression. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 47-52.	3.2	19
122	Rating well-being and distress. Stress and Health, 2000, 16, 55-61.	0.5	76
123	Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary, 2000, 3, 55-59.	2.9	40
124	Rating well-being and distress. , 2000, 16, 55.		1
125	Rating wellâ€being and distress. Stress and Health, 2000, 16, 55-61.	0.5	4
126	New psychotherapeutic approaches to residual symptoms and relapse prevention in unipolar depression. Clinical Psychology and Psychotherapy, 1999, 6, 194-201.	2.7	7

#	Article	IF	CITATIONS
127	Potential Sensitising Effects of Antidepressant Drugs on Depression. CNS Drugs, 1999, 12, 247-256.	5.9	14
128	Subclinical symptoms in mood disorders: pathophysiological and therapeutic implications. Psychological Medicine, 1999, 29, 47-61.	4.5	260
129	Psychological aspects of endocrine disease. Clinical Endocrinology, 1998, 49, 1-7.	2.4	39
130	Conceptual Obstacles to Research Progress in Affective Disorders. Psychotherapy and Psychosomatics, 1997, 66, 283-285.	8.8	24
131	Screening and Diagnosis of Depression. Disease Management and Health Outcomes, 1997, 2, 1-7.	0.4	7
132	Depression Associated with Medical Illness. CNS Drugs, 1996, 5, 175-189.	5.9	43
133	Low impact. Nature, 1996, 382, 750-750.	27.8	1
134	The Concept of Recovery in Affective Disorders. Psychotherapy and Psychosomatics, 1996, 65, 2-13.	8.8	102
135	Long-Term Effects of Behavioural Treatment for Panic Disorder with Agoraphobia. British Journal of Psychiatry, 1995, 166, 87-92.	2.8	99
136	Diagnostic Criteria for Use in Psychosomatic Research. Psychotherapy and Psychosomatics, 1995, 63, 1-8.	8.8	329
137	Sulpiride and Tardive Dyskinesia. CNS Drugs, 1995, 3, 237.	5.9	1
138	Do Antidepressanf and Antianxiety Drugs Increase Chronicity in Affective Disorders?. Psychotherapy and Psychosomatics, 1994, 61, 125-131.	8.8	69
139	A role for life events in the pathogenesis of Cushing's disease. Clinical Endocrinology, 1993, 38, 261-264.	2.4	53
140	Anxiety sensitivity in essential hypertension. Stress and Health, 1992, 8, 113-115.	0.5	4
141	Irritable mood and physical illness. Stress and Health, 1987, 3, 293-299.	0.5	27
142	Psychiatric symptomatology in secondary amenorrhea. Stress and Health, 1986, 2, 191-193.	0.5	0
143	Psychological reactions to fetoscopy: A controlled study. Prenatal Diagnosis, 1984, 4, 397-404.	2.3	14
144	Incorporating the Insights of Psychotherapy Research in Everyday Practice., 0,, 135-136.		0